Phylo, Inc. announced a partnership with Bayer on Oct. 22 to use its Biomni Lab AI platform in drug-discovery research, including workflows aimed at assembling scientific literature and omics evidence.
Phylo said Bayer would receive full access. One section of the announcement described access as forthcoming, while another said Biomni Lab was already used by Bayer. The company did not clarify whether access had begun or provide a rollout schedule. It disclosed no financial terms, participating research teams or deployment details.
Phylo describes Biomni Lab as an environment for research papers, biomedical data and analysis tools. The company says researchers can inspect the evidence and analytical steps associated with an output. The Bayer workflows are intended to bring literature and omics evidence together for drug-discovery research. Phylo says the platform aims to reduce manual work in assembling and assessing information, but it provided no performance results from Bayer or measured time savings.
The announcement did not identify data integrations or explain how access would be configured across Bayer research groups. It also gave no metric for judging the platform or reported effect on the pace or outcomes of research.
Sai Jasti, Bayer Pharmaceuticals R&D's senior vice president and head of data science and artificial intelligence, said the collaboration is meant to help scientists pursue more ideas in drug discovery. “AI should expand scientific curiosity, not just speed up routine work,” Jasti said.
Kexin Huang, Ph.D., Phylo's co-founder and CEO, said the platform needs to gain scientists' confidence. “it has to earn the trust of the scientists doing the work,” Huang said.
Phylo has also announced Biomni Lab collaborations for drug-discovery work with Ono Pharmaceutical in July 2026 and Chugai Pharmaceutical in August 2026. The company says it is based in South San Francisco and backed by Andreessen Horowitz (a16z) and Menlo Ventures.
